NHNaoko Hattori

Naoko Hattori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naoko Hattori has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Toshikazu Ushijima

    Department of Epigenomics, Institute for Advanced Life Sciences, Hoshi University, Tokyo, Japan

    11 shared publications
  • Satoshi Yamashita

    Department of Life Engineering, Faculty of Engineering, Maebashi Institute of Technology, Maebashi, Japan

    4 shared publications
  • Hiroshi Ureshino

    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine Saga University, Saga, Japan

    3 shared publications
  • Shinya Kimura

    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine Saga University Saga Japan

    3 shared publications
  • Atsushi Kawaguchi

    Center for Comprehensive Community Medicine, Faculty of Medicine, Saga University, Saga, Japan

    2 shared publications
  • Kana Kimura

    Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan

    2 shared publications

Latest Publications

  • Open Access

    Super‐Enhancer Formation in Scirrhous Gastric CAFs , and the Presence of a Stromal Field in Non‐Cancerous Tissues

    by Yoshimi Yasukawa, Naoko Hattori, Yu‐Yu Liu, Masayuki Tobo, Genki Yamagishi, Takahiro Irie, Shigeki Sekine, Tohru Kiyono, Satoshi Yamashita, Yukinori Yamagata, et al.

    Scirrhous gastric cancer has aggressive clinical courses and is characterized by dominating cancer‐associated fibroblasts (CAFs). However, the origin of scirrhous CAFs remains unclear, and we here aimed to explore the epigenetic basis for scirrhous CAFs and their origin. Conditioned medium (CM) from scirrhous CAFs was shown to have a marked effect (2–4 folds) on the migration of gastric cancer cells compared to that from non‐scirrhous CAFs. The aggressive phenotype of scirrhous CAFs was associated with activation of TGFβ1 and NF‐κB, along with increased expression of their downstream genes. Scirrhous CAFs had heavily acetylated super‐enhancers, and therapeutic targeting of super‐enhancers by a BET bromodomain inhibitor, mivebresib and JQ‐1, markedly decreased their migration‐promoting activity. Notably, in scirrhous gastric cancer patients, normal fibroblasts in non‐cancerous tissues also had a strong migration‐promoting effect. It was suggested that fibroblasts in the non‐cancerous tissue of scirrhous gastric patients have already acquired tumor‐promoting capacity, forming a stromal field for scirrhous gastric cancer although its spatial extent remains to be solved.

  • Open Access

    Synthetic lethality of EZH2 and DNMT Inhibition suppresses neuroblastoma proliferation via MYCN destabilization

    by Yuki Endo, Ryuichi P. Sugino, Hisanori Takenobu, Kyosuke Mukae, Ryu Okada, Yoshitaka Shinno, Masayuki Haruta, Shunpei Satoh, Jesmin Akter, Naoko Hattori, et al.

    Enhancer of Zeste Homolog 2 (EZH2) is highly expressed in various cancers and is thought to contribute to cancer malignancy through the methylation of lysine 27 on histone H3 (H3K27). Therefore, EZH2 is an H3K27 methylase and a target of cancer epigenetic treatments. Here, we investigated the effects and functions of a small-molecule EZH2 inhibitor (EZH2i) in aggressive neuroblastoma (NB). To identify genes associated with the sensitivity to EZH2i, we classified NB cell lines into sensitive and resistant groups. EZH2i suppressed proliferation and induced cell cycle arrest in EZH2-sensitive NB cells. Transcriptome analysis revealed the de-repression of gene sets related to differentiation and cell cycle arrest. To investigate whether the gene repression in resistant cells is mediated by mechanisms other than H3K27 methylation, methylome analysis was conducted to evaluate the significance of DNA methylation. The effect of combined treatment with an EZH2 inhibitor and a DNA methylation inhibitor (DNMTi) on the growth of resistant NB cells was subsequently assessed both in vitro and in vivo, even in cells resistant to EZH2 inhibition. Genes such as TRIM63, VSTM2L, GPNMB, and TIMP3, which are de-repressed by EZH2is in sensitive cells. Furthermore, the promoters of some of these genes are hypermethylated in EZH2i-resistant cells and NB tissues. Additionally, the combined treatment with EZH2i and 5-aza-dC significantly inhibited cell proliferation with MYCN destabilization at protein level, c-MYC suppression at RNA and protein level and induced a robust differentiation phenotype. Our study identified gene expression profiles that can distinguish the responsiveness to EZH2i in neuroblastoma, and demonstrated that DNMTi not only de-repression in gene expression but also suppress neuroblastoma growth through inhibition of MYC. These results confirm the importance of epigenetic regulation in NB biology and provide information for developing epigenetic therapies for patients with advanced NB.


  • Open Access

    Epigenetic disruption of adipogenic gene enhancers in dedifferentiated liposarcomas and its therapeutic value

    by Naoko Hattori, Hironori Takamatsu, Naoko Iida, Naofumi Asano, Satoshi Yamashita, Gina Miku Oba, Kozue Kimura, Akihiko Yoshida, Eisuke Kobayashi, Robert Nakayama, et al.

    Liposarcoma (LPS) is the most common soft-tissue sarcoma in adults, and well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are the most frequent subtypes. These LPSs are considered to develop due to disturbances in the adipogenic differentiation of mesenchymal stem cells. However, the molecular mechanisms underlying the disturbances remain unclear. Here, we aimed to identify the mechanism and explore its therapeutic advantages focusing upon their epigenetic alterations, known to be important in differentiation. First, we conducted a genome-wide DNA methylation analysis using 15 LPSs (6 WDLPSs and 9 DDLPSs) and 6 normal adipose tissues. Unsupervised hierarchical cluster analysis using DNA methylation profiles at enhancers classified the samples into the three histological types, whereas analysis using promoters did not. Principal component analysis revealed that normal adipose tissues and WDLPSs were grouped closely, whereas DDLPSs were scattered. Genomic regions hypermethylated in DDLPSs were enriched for enhancers, especially super-enhancers (13.5% of hypermethylated regions and 7.0% of the whole genome), which were located in the genes involved in adipogenesis, such as PPARG2 and its target genes (FABP4 and PLIN1). In addition, marked decreases in PPARG2 and FABP4 expression were confirmed in DDLPSs. Then, treatment of PPARG2-expressing DDLPS cell lines with 5-aza-2’-deoxycytidine, a DNA demethylating agent, and rosiglitazone, a PPARγ agonist, was shown to induce differentiation with enhanced expression of FABP4. These findings indicate that aberrant DNA methylation of adipogenic gene enhancers plays a crucial role in the development of DDLPS and can be a therapeutic target.


  • Open Access

    Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors

    by Takuya Azechi, Yutaka Fukaya, Chika Nitani, Junichi Hara, Hiroshi Kawamoto, Tomoaki Taguchi, Kenichi Yoshimura, Akihiro Sato, Naoko Hattori, Toshikazu Ushijima, et al.

    Tamibarotene is a synthetic retinoid that inhibits tumor cell proliferation and promotes differentiation. We previously reported on the safety and tolerability of tamibarotene in patients with recurrent or refractory solid tumors. Therefore, in this study, we aimed to evaluate the pharmacokinetic properties of tamibarotene and construct a precise pharmacokinetic model. We also conducted a non-compartmental analysis and population pharmacokinetic (popPK) analysis based on the results of a phase I study. Targeted pediatric and young adult patients with recurrent or refractory solid tumors were administered tamibarotene at doses of 4, 6, 8, 10, and 12 g/m2/day. Serum tamibarotene concentrations were evaluated after administration, and a popPK model was constructed for tamibarotene using Phoenix NLME. During model construction, we considered the influence of various parameters (weight, height, body surface area, and age) as covariates. Notably, 22 participants were included in this study, and 109 samples were analyzed. A two-compartment model incorporating lag time was selected as the base model. In the final model, the body surface area was included as a covariate for apparent total body clearance, the central compartment volume of distribution, and the peripheral compartment volume of distribution. Visual prediction checks and bootstrap analysis confirmed the validity and predictive accuracy of the final model as satisfactory.


  • Open Access

    Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL

    by Yuki Kurahashi, Tatsuro Watanabe, Yuta Yamamoto, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Satoshi Yamashita, Naoko Hattori, Hideaki Nakamura, et al.

    Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature CD4+ T cells caused by human T-cell lymphotropic virus type 1 (HTLV-1)–induced T-cell transformation. After infection with HTLV-1, it takes several decades for HTLV-1 carriers to develop ATL. The prognosis of ATL remains poor despite several new agents being approved in the last few years. Recently, it has been noted that epigenetic abnormalities, both DNA methylation and trimethylation at histone H3Lys27 (H3K27me3), contribute to ATL leukemogenesis. Here, we investigated the effect of combination treatment with DNA demethylating agents (azacitidine [AZA], decitabine (DAC), and OR-2100 (OR21), which is a silylated derivative of DAC) and inhibitors of enhancer of zeste homolog 2 (EZH2) (EPZ-6438 and DS-3201b), which catalyze trimethylation of H3K27, in ATL. The combination of DAC and OR21 but not AZA with EZH inhibitors exhibited synergistic anti-ATL effects in vitro and in vivo, concomitant with DNA demethylation and reduction of H3K27me3. The combination induced gene expression reprogramming. Dual-specificity phosphatase 5 (DUSP5), an extracellular signal-regulated kinase (ERK)–specific phosphatase, was identified as a key molecule that mediated the inhibitory effect of combination treatment by inactivating the ERK signaling pathway. DUSP5 was downregulated by DNA methylation and H3K27me3 accumulation in the promoter region in HTLV-1–infected cells from patients with ATL during ATL leukemogenesis. The present results demonstrate that dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth by restoring DUSP5, and that dual targeting of aberrant DNA and histone methylation is a feasible therapeutic approach for ATL.


  • Open Access

    A quantification method of somatic mutations in normal tissues and their accumulation in pediatric patients with chemotherapy

    by Sho Ueda, Satoshi Yamashita, Miho Nakajima, Tadashi Kumamoto, Chitose Ogawa, Yu-Yu Liu, Harumi Yamada, Emi Kubo, Naoko Hattori, Hideyuki Takeshima, et al.

    Somatic mutations are accumulated in normal human tissues with aging and exposure to carcinogens. If we can accurately count any passenger mutations in any single DNA molecule, since their quantity is much larger than driver mutations, we can sensitively detect mutation accumulation in polyclonal normal tissues. Duplex sequencing, which tags both DNA strands in one DNA molecule, enables accurate count of such mutations, but requires a very large number of sequencing reads for each single sample of human-genome size. Here, we reduced the genome size to 1/90 using the Bam HI restriction enzyme and established a cost-effective pipeline. The enzymatically cleaved and optimal sequencing (EcoSeq) method was able to count somatic mutations in a single DNA molecule with a sensitivity of as low as 3 × 10 −8 per base pair (bp), as assessed by measuring artificially prepared mutations. Taking advantages of EcoSeq, we analyzed normal peripheral blood cells of pediatric sarcoma patients who received chemotherapy ( n = 10) and those who did not ( n = 10). The former had a mutation frequency of 31.2 ± 13.4 × 10 −8 per base pair while the latter had 9.0 ± 4.5 × 10 −8 per base pair ( P < 0.001). The increase in mutation frequency was confirmed by analysis of the same patients before and after chemotherapy, and increased mutation frequencies persisted 46 to 64 mo after chemotherapy, indicating that the mutation accumulation constitutes a risk of secondary leukemia. EcoSeq has the potential to reveal accumulation of somatic mutations and exposure to environmental factors in any DNA samples and will contribute to cancer risk estimation.


  • Combination of a synthetic retinoid and a DNA demethylating agent induced differentiation of neuroblastoma through retinoic acid signal reprogramming

    by Naoko Hattori, Kiyoshi Asada, Nozomu Miyajima, Akiko Mori, Yoko Nakanishi, Kana Kimura, Mika Wakabayashi, Hideyuki Takeshima, Chika Nitani, Junichi Hara, et al.

    Background The CpG island methylator phenotype of neuroblastoma (NBL) is strongly associated with poor prognosis and can be targeted by 5-aza-2’-deoxycytidine (5-aza-dC). Differentiation therapy is a standard maintenance therapy for high-risk NBLs. However, the in vivo effect of tamibarotene, a synthetic retinoic acid, and the efficacy of its combination with 5-aza-dC have not been studied. Here, we conducted a preclinical study to assess the in vivo tamibarotene effect and the combination. Methods Treatment effects were analysed by in vitro cell growth and differentiation state and by in vivo xenograft suppression. Demethylated genes were analysed by DNA methylation microarrays and geneset enrichment. Results Tamibarotene monotherapy induced neural extension and upregulation of differentiation markers of NBL cells in vitro, and tumour regression without severe side effects in vivo. 5-Aza-dC monotherapy suppressed tumour growth both in vitro and in vivo, and induced demethylation of genes related to nervous system development and function. Pre-treatment with 5-aza-dC in vitro enhanced upregulation of differentiation markers and genes involved in retinoic acid signaling. Pre-treatment with 5-aza-dC in vivo significantly suppressed tumour growth and reduced the variation in tumour sizes. Conclusions Epigenetic drug-based differentiation therapy using 5-aza-dC and TBT is a promising strategy for refractory NBLs.


  • Open Access

    Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects

    by Hiroshi Ureshino, Yuki Kurahashi, Tatsuro Watanabe, Satoshi Yamashita, Kazuharu Kamachi, Yuta Yamamoto, Yuki Fukuda-Kurahashi, Nao Yoshida-Sakai, Naoko Hattori, Yoshihiro Hayashi, et al.

    DNA methyltransferase inhibitors have improved the prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, because these agents are easily degraded by cytidine deaminase (CDA), they must be administered intravenously or subcutaneously. Recently, two orally bioavailable DNA methyltransferase inhibitors, CC-486 and ASTX727, were approved. In previous work, we developed 5-O-trialkylsilylated decitabines that resist degradation by CDA. However, the effects of silylation of a deoxynucleotide analog and enzymatic cleavage of silylation have not been fully elucidated. Enteric administration of OR21 in a cynomolgus monkey model led to high plasma concentrations and hypomethylation, and in a mouse model, oral administration of enteric-coated OR21 led to high plasma concentrations. The drug became biologically active after release of decitabine (DAC) from OR21 following removal of the 5′-O-trisilylate substituent. Toxicities were tolerable and lower than those of DAC. Transcriptome and methylome analysis of MDS and AML cell lines revealed that OR21 increased expression of genes associated with tumor suppression, cell differentiation, and immune system processes by altering regional promoter methylation, indicating that these pathways play pivotal roles in the action of hypomethylating agents. OR21 induced cell differentiation via upregulation of the late cell differentiation drivers CEBPE and GATA-1. Thus, silylation of a deoxynucleotide analog can confer oral bioavailability without new toxicities. Both in vivo and in vitro, OR21 exerted antileukemia effects, and had a better safety profile than DAC. Together, our findings indicate that OR21 is a promising candidate drug for phase I study as an alternative to azacitidine or decitabine.


  • Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

    by Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Nao Yoshida, Naoko Hattori, Hideaki Nakamura, Akemi Sato, et al.

    Adult T-cell leukemia-lymphoma (ATL) is an aggressive hematological malignancy of CD4+ T-cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Most HTLV-1-infected individuals are asymptomatic and only 3-5% of carriers develop ATL. Here, we describe the contribution of aberrant DNA methylation to ATL leukemogenesis. HTLV-1-infected T-cells and their uninfected counterparts were separately isolated based on CADM1 and CD7 expression status, and differentially methylated positions (DMPs) specific to HTLV-infected T-cells were identified through genome-wide DNA methylation profiling. Accumulation of DNA methylation at hypermethylated DMPs correlated strongly with ATL development and progression. In addition, we identified 22 genes down-regulated due to promoter hypermethylation in HTLV-1-infected T-cells, including THEMIS, LAIR1, and RNF130, which negatively regulate T-cell receptor (TCR) signaling. Phosphorylation of ZAP-70, a transducer of TCR signaling, was dysregulated in HTLV-1-infected cell lines but was normalized by re-expression of THEMIS. Therefore, we hypothesized that DNA hypermethylation contributes to growth advantages in HTLV-1-infected cells during ATL leukemogenesis. To test this idea, we investigated the anti-ATL activities of OR-1200 and OR-2100 (OR21), novel decitabine (DAC) prodrugs with enhanced oral bioavailability. Both DAC and OR21 inhibited cell growth, accompanied by global DNA hypomethylation, in xenograft tumors established by implantation of HTLV-1-infected cells. OR21 was less hematotoxic than DAC, whereas tumor growth inhibition was almost identical between the two compounds, making it suitable for long-term treatment of ATL patient-derived xenograft mice. Our results demonstrate that regional DNA hypermethylation is functionally important for ATL leukemogenesis and an effective therapeutic target.


  • Open Access

    Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways

    by Hiroshi Moro, Naoko Hattori, Yoshiaki Nakamura, Kana Kimura, Toshio Imai, Masahiro Maeda, Masakazu Yashiro, Toshikazu Ushijima

    Gastric cancer is heavily influenced by aberrant DNA methylation that alters multiple cancer-related pathways, and may respond to DNA demethylating agents, such as 5-aza-2′-deoxycytidine (5-aza-dC). Here, we aimed to analyze whether 5-aza-dC can sensitize gastric cancer cells to clinically used cytotoxic drugs.